PAREXEL's ClinPhone RTSM Cuts Clinical Trial Start-Up Time - Analyst Blog

Global biopharmaceutical services organization, PAREXEL International Corporation PRXL launched a new version of its industry standard ClinPhone RTSM (Randomization and Trial Supply Management) solution designed to help start clinical trials more quickly. Following the announcement, shares of PAREXEL climbed 2.2% to close at $53.67 yesterday.

The latest version of the ClinPhone RTSM solution has been developed by PAREXEL Informatics – PAREXEL's wholly owned technology subsidiary, which acquired ClinPhone Plc – a clinical technology organization, in 2008.

At the start of a clinical trial, clients have to simultaneously initiate a broad range of important activities such as patient screening, enrollment and randomization, drug dispensation and supply distribution. PAREXEL's ClinPhone RTSM is incorporated with flexible, pre-built and interactive web modules that allow rapid implementation of patient, supplies and site management activities.

As part of the ClinPhone RTSM solution, its web modules provide extended functionality and place increased administrative and management control in the hands of the study teams. Integrated with the latest RTSM technology that features standardized study components for faster implementation and greater design flexibility, the study teams can start their trials more quickly.

RTSM solution is a key component of PAREXEL's proprietary Perceptive MyTrials platform, an integrated suite of applications for managing clinical trials. The leading edge solution has been used in more than 3,000 studies involving over 400,000 sites and two million patients since 1993.

PAREXEL's ClinPhone RTSM is available as a standalone solution as well as through the Perceptive MyTrials platform. ClinPhone RTSM and the Perceptive MyTrials platform are also available through the company's Perceptive Partner Program.

PAREXEL intends to meet the increasing need for conducting faster and more efficient trials by making considerable investments in developing cutting-edge technology. It is also focusing on making drug development more efficient, without compromising on patient safety or data quality.

Currently, PAREXEL has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical services industry include ICON Public Limited Company ICLR, BG Medicine, Inc. BGMD and Omnicare Inc. OCR. While ICON Public Limited Company sports a Zacks Rank #1 (Strong Buy), both BG Medicine and Omnicare carry a Zacks Rank #2 (Buy).